{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:23:13Z","timestamp":1764937393911,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.cld.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T07:27:09Z","timestamp":1648798029000},"page":"181-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hepatorenal Syndrome"],"prefix":"10.1016","volume":"26","author":[{"given":"Sebastiano","family":"Buccheri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben L.","family":"Da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2022.01.002_bib1","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s10620-019-05858-2","article-title":"Limited progress in hepatorenal syndrome (HRS) reversal and survival 2002-2018: a systematic review and meta-analysis","volume":"65","author":"Thomson","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2022.01.002_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document","volume":"71","author":"Angeli","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"64","author":"Angeli","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cld.2022.01.002_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2215\/CJN.12451018","article-title":"Hepatorenal syndrome","volume":"14","author":"Francoz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cld.2022.01.002_bib9","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.24786","article-title":"Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials","volume":"55","author":"Bernardi","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"341","author":"Sort","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2022.01.002_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1155\/2011\/586702","article-title":"Should albumin be used in all patients with spontaneous bacterial peritonitis?","volume":"25","author":"Narula","year":"2011","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cld.2022.01.002_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ejim.2013.05.015","article-title":"Clinical indications for the albumin use: still a controversial issue","volume":"24","author":"Caraceni","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cld.2022.01.002_bib13","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2022.01.002_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","article-title":"Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis","volume":"133","author":"Fern\u00e1ndez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.01.002_bib15","first-page":"153","article-title":"Albumin administration is efficacious in the management of patients with cirrhosis: a systematic review of the literature","volume":"12","author":"Zaccherini","year":"2020","journal-title":"Hepat Med"},{"key":"10.1016\/j.cld.2022.01.002_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1478-3231.2010.02272.x","article-title":"Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis","volume":"30","author":"Salerno","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2022.01.002_bib17","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3748\/wjg.v12.i9.1403","article-title":"Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial","volume":"12","author":"Romanelli","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2022.01.002_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.13968","article-title":"Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites","volume":"39","author":"Di Pascoli","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2022.01.002_bib19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa2022166","article-title":"A\u00a0randomized trial of albumin infusions in hospitalized patients with cirrhosis","volume":"384","author":"China","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2022.01.002_bib20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27015","article-title":"Hepatorenal syndrome type 1 and bacterial infection: a catastrophic association in patients with cirrhosis","volume":"59","author":"Salerno","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cld.819","article-title":"Prophylactic antibiotics in cirrhosis: are they promoting or preventing infections?","volume":"14","author":"Garcia-Tsao","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.cld.2022.01.002_bib22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cgh.2019.07.055","article-title":"Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis","volume":"18","author":"Fern\u00e1ndez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/MEG.0000000000000940","article-title":"Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis","volume":"29","author":"Kamal","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2174\/1389450119666180924145156","article-title":"Safety and efficacy of rifaximin in prophylaxis of spontaneous bacterial peritonitis: a systematic review and meta-analysis","volume":"20","author":"Menshawy","year":"2019","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.cld.2022.01.002_bib25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.1840200619","article-title":"Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis","volume":"20","author":"Follo","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib26","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1053\/jhep.2003.50447","article-title":"Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis","volume":"38","author":"Ruiz-del-Arbol","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib27","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/hep.28330","article-title":"Antibiotic prophylaxis in cirrhosis: good and bad","volume":"63","author":"Fern\u00e1ndez","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/gut.2009.180570","article-title":"Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites","volume":"59","author":"Krag","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cld.2022.01.002_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/apt.14366","article-title":"Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation","volume":"47","author":"Bhutta","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2022.01.002_bib30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.01.002_bib31","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib32","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib33","first-page":"1008","article-title":"Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices","volume":"52","author":"Scheiner","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2022.01.002_bib34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","article-title":"Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure","volume":"64","author":"Mookerjee","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib35","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/gutjnl-2011-301348","article-title":"The window hypothesis: haemodynamic and non-haemodynamic effects of \u03b2-blockers improve survival of patients with cirrhosis during a window in the disease","volume":"61","author":"Krag","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cld.2022.01.002_bib36","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib37","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/lt.26072","article-title":"The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin","volume":"27","author":"Flamm","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2022.01.002_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis","volume":"2","author":"Facciorusso","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MCG.0000000000000913","article-title":"Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis","volume":"52","author":"Nanda","year":"2018","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2022.01.002_bib40","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2022.01.002_bib41","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MCG.0b013e318188947c","article-title":"Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome","volume":"43","author":"Skagen","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2022.01.002_bib42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib43","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12664-018-0876-3","article-title":"Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study","volume":"37","author":"Saif","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.cld.2022.01.002_bib45","doi-asserted-by":"crossref","first-page":"675948","DOI":"10.3389\/fphar.2021.675948","article-title":"Norepinephrine is more effective than midodrine\/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial","volume":"12","author":"El-Desoki Mahmoud","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cld.2022.01.002_bib46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib47","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.01.002_bib48","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study","volume":"33","author":"Ghosh","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2022.01.002_bib49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12072-014-9580-2","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) 2014","volume":"8","author":"Sarin","year":"2014","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2022.01.002_bib51","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12072-019-09980-1","article-title":"Correction to: acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update","volume":"13","author":"Sarin","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2022.01.002_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib53","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.01.002_bib54","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A\u00a0randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.01.002_bib55","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.01.002_bib56","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2022.01.002_bib57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/apt.13912","article-title":"Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1","volume":"45","author":"Gifford","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2022.01.002_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","article-title":"Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics","volume":"55","author":"Boyer","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","author":"Nazar","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2015.12.003","article-title":"Dopamine and furosemide for the treatment of hepatorenal syndrome: a reappraisal or just smoke and mirrors?","volume":"5","author":"Piano","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib61","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archinte.1975.00330070086014","article-title":"Response to dopamine hydrochloride in the hepatorenal syndrome","volume":"135","author":"Bennett","year":"1975","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cld.2022.01.002_bib62","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine","volume":"30","author":"G\u00fclberg","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jceh.2015.08.003","article-title":"Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome","volume":"5","author":"Srivastava","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00240-018-1072-8","article-title":"Protective effect of pentoxifylline on oxidative renal cell injury associated with renal crystal formation in a hyperoxaluric rat model","volume":"47","author":"Ozturk","year":"2019","journal-title":"Urolithiasis"},{"key":"10.1016\/j.cld.2022.01.002_bib65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MEG.0b013e3283435d76","article-title":"Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo","volume":"23","author":"Tyagi","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib66","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5604\/01.3001.0010.8661","article-title":"Treatment of Type-1 hepatorenal syndrome with pentoxifylline: a randomized placebo controlled clinical trial","volume":"17","author":"Stine","year":"2018","journal-title":"Ann Hepatol"},{"author":"Jamie","key":"10.1016\/j.cld.2022.01.002_bib67"},{"key":"10.1016\/j.cld.2022.01.002_bib68","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/hep.26886","article-title":"Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis","volume":"59","author":"De Souza","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib69","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/lt.22128","article-title":"Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score","volume":"16","author":"Francoz","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2022.01.002_bib70","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/ndt\/gfs067","article-title":"Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis","volume":"27","author":"Schrier","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cld.2022.01.002_bib71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.semvascsurg.2017.04.001","article-title":"Management of renal dysfunction in patients with liver cirrhosis: role of pretransplantation hemodialysis and outcomes after liver transplantation","volume":"29","author":"Thorat","year":"2016","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.cld.2022.01.002_bib72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/08860229509026250","article-title":"Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis","volume":"17","author":"Keller","year":"1995","journal-title":"Ren Fail"},{"key":"10.1016\/j.cld.2022.01.002_bib73","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/sdi.12224","article-title":"Is there a role for dialysis in patients with hepatorenal syndrome who are not liver transplant candidates?","volume":"27","author":"Belcher","year":"2014","journal-title":"Semin Dial"},{"key":"10.1016\/j.cld.2022.01.002_bib74","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ndt\/gfi212","article-title":"The course of type 1 hepato-renal syndrome post liver transplantation","volume":"21","author":"Marik","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.cld.2022.01.002_bib75","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/ki.2013.78","article-title":"Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction","volume":"84","author":"van Slambrouck","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.cld.2022.01.002_bib76","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1081\/JDI-200035988","article-title":"The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis","volume":"26","author":"Capling","year":"2004","journal-title":"Ren Fail"},{"key":"10.1016\/j.cld.2022.01.002_bib77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2215\/CJN.03610417","article-title":"Prognosis of patients with cirrhosis and AKI who initiate RRT","volume":"13","author":"Allegretti","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cld.2022.01.002_bib78","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1440-1746.2004.03471.x","article-title":"Which patients benefit from hemodialysis therapy in hepatorenal syndrome?","volume":"19","author":"Witzke","year":"2004","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib79","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/j.1600-6143.2008.02416.x","article-title":"Proceedings of consensus Conference on simultaneous liver kidney transplantation (SLK)","volume":"8","author":"Eason","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2022.01.002_bib80","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1600-6143.2007.01856.x","article-title":"Simultaneous liver-kidney transplantation: evaluation to decision making","volume":"7","author":"Davis","year":"2007","journal-title":"Am J Transpl"},{"key":"10.1016\/j.cld.2022.01.002_bib81","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1111\/j.1600-6143.2012.04190.x","article-title":"Simultaneous liver-kidney transplantation summit: current state and future directions","volume":"12","author":"Nadim","year":"2012","journal-title":"Am J Transpl"},{"key":"10.1016\/j.cld.2022.01.002_bib82","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2012.06.024","article-title":"Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice","volume":"57","author":"Angeli","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib83","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.ajkd.2011.07.017","article-title":"Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials","volume":"58","author":"Velez","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cld.2022.01.002_bib84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4254\/wjh.v9.i6.293","article-title":"Hepatorenal syndrome: update on diagnosis and therapy","volume":"9","author":"Acevedo","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib85","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clinre.2019.09.003","article-title":"TIPS for management of portal-hypertension-related complications in patients with cirrhosis","volume":"44","author":"Allaire","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cld.2022.01.002_bib86","first-page":"1753","article-title":"Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation","volume":"50","author":"Testino","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.cld.2022.01.002_bib87","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.510280219","article-title":"Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems","volume":"28","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib88","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13613-018-0453-z","article-title":"Artificial liver support systems: what is new over the last decade?","volume":"8","author":"Garc\u00eda Mart\u00ednez","year":"2018","journal-title":"Ann Intensive Care"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2022.01.002_bib89","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1665-2681(19)31602-3","article-title":"Extracorporeal liver support-albumin dialysis with the molecular adsorbent recirculating system (MARS)","volume":"10","author":"Mitzner","year":"2011","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cld.2022.01.002_bib90","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/lt.500060326","article-title":"Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial","volume":"6","author":"Mitzner","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2022.01.002_bib91","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/hep.26185","article-title":"Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial","volume":"57","author":"Ba\u00f1ares","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib92","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.01.002_bib93","doi-asserted-by":"crossref","first-page":"e107466","DOI":"10.1371\/journal.pone.0107466","article-title":"Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis","volume":"9","author":"Nassar Junior","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2022.01.002_bib94","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:58:13Z","timestamp":1761069493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1089326122000022"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.01.002","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatorenal Syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}